

A comprehensive evaluation of the potential binding poses of fentanyl and its analogs  
at the  $\mu$ -opioid receptor

Bing Xie<sup>1</sup>, Alexander Goldberg<sup>1</sup>, Lei Shi<sup>1,\*</sup>

<sup>1</sup>Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications  
Discovery Branch, National Institute on Drug Abuse – Intramural Research Program, National  
Institutes of Health, Baltimore, MD 21224, USA

\*corresponding author: [lei.shi2@nih.gov](mailto:lei.shi2@nih.gov)

## **Abstract**

Fentanyl and its analogs are selective agonists of the  $\mu$ -opioid receptor (MOR). Among novel synthetic opioids (NSOs), they dominate the recreational drug market and are the main culprits for the opioid crisis, which has been exacerbated by the COVID-19 pandemic. By taking advantage of the crystal structures of the MOR, several groups have investigated the binding mechanism of fentanyl, but have not reached a consensus, in terms of both the binding orientation and the fentanyl conformation. Thus, the binding mechanism of fentanyl at the MOR remains an unsolved and challenging question. Here, we carried out a systematic computational study to investigate the preferred fentanyl conformations, and how these conformations are being accommodated in the MOR binding pocket. We characterized the free energy landscape of fentanyl conformations with metadynamics simulations, as well as performed long-timescale molecular dynamics simulations to compare and evaluate several possible fentanyl binding conditions. Our results indicate that the most preferred binding pose in the MOR binding pocket corresponds well with the minima on the energy landscape of fentanyl in the absence of the receptor, while the energy landscape can be reconfigured by modifying the fentanyl scaffold. The interactions with the receptor may stabilize a slightly unfavored fentanyl conformation in an alternative binding pose. By extending similar investigations to fentanyl analogs, our findings establish a structure-activity relationship of fentanyl binding at the MOR. In addition to providing a structural basis to understand the potential toxicity of the emerging NSOs, such insights will contribute to developing new, safer analgesics.

## **Keywords**

Fentanyl,  $\mu$ -opioid receptor, molecular dynamics simulations, metadynamics, structure-activity relationship

## 1. Introduction

Selective agonists of the  $\mu$ -opioid receptor (MOR), such as morphine, codeine, and meperidine, have a long history of being used as analgesics to relieve pains [1]. Based on meperidine, which shares the piperidine core with morphine, Janssen and his colleagues discovered fentanyl in 1960 [2]. Fentanyl is easy to synthesize, and much more potent in analgesic effect, but has higher addiction liability than morphine [1-3]. Fentanyl and its analogs dominate the current recreational drug market [4] and are the main culprits for the ongoing and growing opioid crisis [5], which has been exacerbated by the COVID-19 pandemic [6].

MOR, a class A G-protein coupled receptor (GPCR), couples with both G-protein and  $\beta$ -arrestin to regulate downstream signaling pathways. The action mechanisms of analgesics at the MOR have been extensively studied for decades (reviewed in [1]). However, whether and how the functional selectivity is involved in inducing the side effects of fentanyl and analgesics in general, such as respiratory suppression, is still being actively studied and debated [7-10].

Early computational studies, based on homology modeling, shed light on the potential binding pose of fentanyl at the MOR [11, 12]. In recent years, high-resolution structures of the MOR have been acquired by both x-ray crystallography [13, 14] and cryo-electron microscopy (cryo-EM) [15], for an inactive conformation of the receptor bound with a morphinan antagonist,  $\beta$ -FNA [14], and active conformations bound with agonists BU72 and DAMGO [13, 15]. These structures have been leveraged to investigate the binding mechanisms, and related MOR conformations, of the opioids having therapeutic implications, such as methadone, morphine, and TRV130 [16, 17].

By taking advantage of these structures, several groups have computationally investigated the binding mechanism of fentanyl and its analogs at the MOR, but they have not reached a consensus [18-24]. While these studies commonly found that the positively charged nitrogen on the piperidine ring forms a salt bridge with Asp<sup>3.32</sup> (superscripts denote Ballesteros-Weinstein

numbering [25]) in the binding site of the MOR, they proposed different binding modes of fentanyl and its analogs. Specifically, based on the crystal structure of the MOR in an active conformation, Vo et al. carried out extensive molecular dynamics (MD) simulations recently and proposed that, in addition to forming a salt-bridge with Asp<sup>3.32</sup> in the orthosteric binding site (OBS), fentanyl can move deeper toward the intracellular side with its positively charged nitrogen forming a hydrogen bond to His<sup>6.52</sup> [23]. They found that the carbonyl and aniline groups of fentanyl point towards the extracellular portions of transmembrane segments (TMs) 2 and 7, an orientation of which is similar to that proposed previously by Lipinski et al. and Eshleman et al. [19, 23, 24] (defined as the phenyl-piperidine-amide (FPA) orientation in **Fig. 1C**). However, using long unbiased MD simulations, Ricarte and colleagues identified an opposite orientation of fentanyl in the binding site of the MOR, with the amide and aniline groups located near the middle portions of TMs 3 and 6 [22] (the amide-piperidine-phenyl (APF) orientation in **Fig. 1B**). The Ricarte pose is similar to that previously proposed by de Waal et al., but in a deeper position in the binding pocket [20, 22]. In addition, the conformations of the bound fentanyl are also different in these studies. The amide bond in the propanamide moiety of fentanyl was in the *cis-amide* configuration in the Ricarte, de Waal, Lipinski, and Eshleman poses [19, 20, 22, 24], and *trans-amide* in the Vo and Podlowska poses [21, 23] (see the *trans* and *cis* configurations in **Fig. 1D**). Together, these studies proposed varied binding poses of fentanyl at the MOR, not only in opposite orientations and different positions in the binding site, but also the divergent fentanyl conformations. Thus, the binding mechanisms of fentanyl at the MOR remains an unsolved and challenging question.

The 3- and 4-positions on the piperidine ring of the fentanyl scaffold have been exploited to develop more potent fentanyl analogs, including carfentanil, 3-methylfentanyl, and lofentanil [2, 26]. In particular, carfentanil has evolved from being used as an animal anesthetic to a deadly abused drug [27], and even has the potential of being used as a chemical weapon [28].

Intriguingly, with the same addition of a 3-methyl moiety, 3-methylfentanyl has much higher potency (as high as ~200-fold, (3R,4S)-isomer) than fentanyl [29, 30], while lofentanil (i.e., 3-methylcarfentanil) only has slightly better affinity at the MOR than carfentanil [31, 32].

Recent literature is confusing about two stereoisomers of lofentanil (**Fig. S1**), (3S,4R)-lofentanil [18, 31] and (3R,4S)-lofentanil [20, 30, 33]. Notably, the lofentanil structures are also divergent in wikipedia (<https://en.wikipedia.org/wiki/Lofentanil>, (3S,4R)-isomer) and PubChem (<https://pubchem.ncbi.nlm.nih.gov/compound/Lofentanil>, (3R,4S)-isomer) as well. Lofentanil was originally referred to the compound having the (3R,4S) chirality, which has three other possible stereoisomers, (3S,4R), (3S,4S), and (3R,4R) [34, 35]. In the context of the potential binding poses in the MOR (see below), these different configurations would position the 3-methyl on the piperidine ring of the fentanyl scaffold to different sides of the 4-carbomethoxy group. While the (-)-cis-isomer has much higher binding affinity than the (+)-cis-isomer, especially in the presence of NaCl (>100-fold), the affinity of the racemic mixture of (+)-trans and (-)-trans-isomers is in between those of the other two isomers [35-38] (Note the *cis* and *trans* configurations referred to here are that of the 3- and 4-modifications but not the amide bond mentioned above). In addition, the (-)-cis-isomer of lofentanil has been found to be the most active and long-acting in both pharmacological and in vivo analgesic tests, but the (+)-cis-isomer was reported to be the first fentanyl derivative having short-acting antagonistic properties [39]. However, the absolute configurations of (-)-cis- and (+)-cis-isomers, i.e., which one is (3R,4S)- and which one is (3S,4R)-configuration, have never been definitively determined by X-ray crystallography.

For 3-methylfentanyl, it has been determined by crystallography that (+)-cis-isomer corresponds to the (3R,4S)-configuration [40], while (-)-cis-(3S,4R)-3-methylfentanyl has drastically lower affinity (> 1000 fold) than its active (+)-cis-(3R,4S)-isomer at the MOR [30, 40]. In addition, a

close analog, ohmefentanyl (**Fig. S1**), was found to have a similar pharmacological profile, with its (3S,4R)-isomers having lower affinity (> 200-fold) than its (3R,4S)-isomers [41].

In this study, we first carried out systematic characterizations of the possible conformations of fentanyl and a few selected analogs with modifications at the 3- and/or 4-positions on the piperidine ring. In the context of the revealed energy landscapes of these ligand conformations in the absence of the receptor, based on the cryo-EM structure of the MOR in complex with the Gi protein [15], we performed long-timescale MD simulations to identify the most favored binding poses of fentanyl and its analogs at the MOR, by comparing the stability and energetics of their possible binding orientations and conformations. We found potential impacts of modifying the fentanyl scaffold on both conformational rigidity and binding potency. We further compared MOR conformations, stabilized by either fentanyl or by DAMGO, to reveal the initial clues about the structural basis of their divergent signaling preferences.

## 2. Materials and Methods

### 2.1. Metadynamics simulations to characterize the free energy landscape

Fentanyl and its analogs were prepared using Ligprep of Schrodinger (version 2020-3). The protonation state of each ligand was determined by Epik of Schrodinger (version 2020-3) in pH  $7.0 \pm 2.0$  condition, which protonates the nitrogen in the piperidine ring of the fentanyl scaffold to the positively charged state. We protonate the nitrogen in the direction observed in the crystal structure of 3-methylfentanyl [40]. For fentanyl and each of its analogs, we immersed the compound in a water box with a dimension of  $30 \times 30 \times 30 \text{ \AA}^3$ , which also included 0.15 M of NaCl. The total number of atoms of each system is  $\sim 2,300$ .

Two dihedral angles of the fentanyl scaffold were selected as collective variables (CV) (**Figure 2C**). The dihedral angle between amide carbonyl and aniline was defined as CV1, and that between aniline and piperidine as CV2. In the metadynamics simulations, the height of the biased Gaussian potential was 0.01 kcal/mol, and the window width was 5 degrees for the CVs. Metadynamics simulations were performed with Desmond [42] (version 2020-3 with the OPLS3e force field [43] and version 2021-2 with the OPLS4 force field [44], Schrodinger LLC, New York, NY, USA). For each compound or isomer, 10 replicate runs were performed – 5 runs were started from each of the CV1 *trans* and *cis* configurations. The length of each run for the fentanyl and carfentanil systems was 100 ns. In order to reach convergence, the runs for the (3S,4R)-lofentanil and (3R,4S)-lofentanil systems were prolonged to 400 ns each. The free energy surface (FES), defined by CV1 and CV2, was rebuilt with the Metadynamics Analysis utility of Schrodinger, with in-house modifications to flexibly increase the number of bins. To integrate the results for each compound or isomer, we carried out 100 bootstrap samplings of the FES from the pool of 10 replicate runs. The averages are shown in **Figs. 2, 3, S2 and S3**, while the standard deviations are shown in **Fig. S4**. The FES was normalized by defining the lowest energy point on the FES as 0.

We implemented Dijkstra's algorithms [45] to identify the minimum free energy path (MFEP) between each pair of local minima. Briefly, we choose one of the local minima as the starting vertex and identify the neighboring vertex that has the lowest energy as the next step on the path and repeat this process. To lead the path towards the targeted minimum, the path is not allowed to revisit the same vertex. The process can generate multiple paths, when more than one neighboring vertex have the same lowest energy. Energy barrier is defined as the difference between the starting vertex and the vertex with the highest energy on the path. The MFEP is identified by finding the path with the lowest energy barrier between two minima. While the MFEP between two minima is unique, the value of energy barrier depends on the starting vertex (**Figs. 2** and **S2, Table S2**).

## **2.2. Energy minimization of the ligand models closest to the minima**

By scanning all frames of metadynamics simulation trajectories, the structures with the shortest Euclidean distance (of CV1 and CV2) to the local minima were extracted. Ligands were separated from the extracted frames and energy minimized through Prime of Schrodinger (Version 2021-1) with the VSGB implicit solvation model to mimic water environment (dielectric constant = 80) [46]. We used the default options except for increasing the maximum number of iterations to 100.

## **2.3. Molecular modeling of the human MOR in an active conformation**

The cryo-EM structure of the mouse MOR (mMOR) in complex with the Gi protein (PDB 6DDF) was used as the main template to build our human MOR (hMOR)-Gi models. In the structure 6DDF, some MOR residues are missing in the N terminus and at H8. We added 8 missing N terminal residues (residues 59-66 in hMOR numbering), present in another MOR structure in an active conformation (PDB 5CM1), and the missing H8 residues (residues 348-354 in hMOR



numbering), from the MOR structure (PDB 4DKL), to the main template using homology modelling with Modeller (version 9.24) [47]. In this modeling process, the structure 5CM1 also provided some missing sidechains in the structure 6DDF, which has relatively low resolution. The added N-terminal residues are necessary to prevent the entry of lipid molecule to the binding pocket in the following molecular dynamics (MD) simulations. In addition, the divergent residues between the mMOR and hMOR in the main template are converted to the aligned human residues (V68<sup>1.30I</sup>, V189<sup>4.45I</sup>, I308<sup>EL3V</sup>). No change or addition was made on the Gi protein template. The hMOR model with the lowest DOPE score was selected for following studies.

#### **2.4. Establish the defined binding modes with molecular docking and manual adjustments**

The selected hMOR model was further processed through the Protein Preparation Wizard in Maestro of Schrodinger. Hydrogen bond assignment was optimized with PROPKA [48] at pH 7.0. Energy minimization of the structure was conducted with the default constraint of 0.3 Å heavy atoms root-mean-square deviation (RMSD). Using the induced-fit docking protocol implemented in Schrodinger [49], we first docked fentanyl in the binding site of the prepared hMOR model. The center of docking box was determined by the center of mass of the ligand bound in the structure 6DDF, DAMGO. We applied a restraint to filter the poses that have the protonated N atom on the piperidine ring forming an ionic interaction with Asp<sup>3.32</sup>. We found both APF and FPA poses in the docking results, and selected or manually adjusted the CV1 dihedral angle, so to acquire both the *trans-amide* and *cis-amide* conformations of each pose. Based on these hMOR models bound with fentanyl in different poses and conformations, we manually modified the fentanyl scaffold to add the extra moieties with the 3D builder in Maestro of

Schrodinger (version 2020-3), and established the corresponding hMOR models bound with carfentanil, (3S,4R)-lofentanil, or (3R,4S)-lofentanil.

## **2.5. Molecular dynamics simulation protocol**

The hMOR models with the defined binding poses of fentanyl and its analogs were further processed to build the simulation systems with the Desmond System Builder of Schrodinger suites (version 2020-3 with OPLS3e force field and version 2021-2 with OPLS4 force field). Briefly, the MOR-Gi complex models were immersed in explicit 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine lipid bilayer (POPC). The simple point charge (SPC) water model was used to solvate the system, the net charge of the system was neutralized by Cl<sup>-</sup> ions, and then 0.15 M NaCl was added. Residues Asp116<sup>2,50</sup> and Asp166<sup>3,49</sup> are protonated to their neutral forms as assumed in the active state of rhodopsin-like GPCRs [50], and we manually adjusted the His299<sup>6,52</sup> protonation form to either HIE or HID as well (see Results). We additionally protonated Asp342<sup>7,57</sup>, which is positioned in between TM7 and H8 and was predicted to be in a neutral protonated state in all MOR structures (6DDF, 5C1M, and 4DKL) by PROPKA. Our test run with Asp342<sup>7,57</sup> deprotonated shows that the negative charge at this location likely destabilized the local interaction network with Gi. The process resulted in a system with a dimension of 106x117x151 Å<sup>3</sup> and total number of atoms of ~190,000. The initial parameters for carfentanil and lofentanil were further optimized by the force field builder of the Schrodinger Suites (version 2020-3 with OPLS3e force field and version 2021-2 with OPLS4 force field). Desmond MD systems (D. E. Shaw Research, New York, NY) was used for the MD simulations. Similar to our previous simulation protocols used for GPCRs [51], the system was initially minimized and equilibrated with restraints on the ligand heavy atoms and protein backbone atoms. The NP<sub>γ</sub>T ensemble was used with constant temperature maintained with Langevin

dynamics. Specifically, 1 atm constant pressure was achieved with the hybrid Nose-Hoover Langevin piston method on an anisotropic flexible periodic cell with a constant surface tension (x-y plane). In the production runs at 310 K, all restraints on the hMOR were released; however, to retain the integrity of the Gi protein, while allowing adequate flexibility to interact with the receptor, the heavy atoms of residues 46-55, 182-189, and 230-242 of G $\alpha$ , and the entire G $\beta$  and G $\gamma$  subunits, were restrained with a force constant of 1 kcal/mol/Å. For each condition, we collected at least three trajectories starting from different random number seeds. Overall, more than 200 trajectories, with an aggregated simulated time of more than 300  $\mu$ s, were collected (**Table S3**).

## 2.6. Conformational analysis

Dihedral angles and distances were calculated with VMD-python (version 3.0.6) [52]. We used the Protein Interaction Analyzer [53, 54] in analyzing the MD simulation results of the MOR. For analysis of coarse-grained interaction network of the hMOR, we defined the following structural elements: TM1e (the extracellular section (e) of TM1, residues 68-74), TM1m (the middle section (m) of TM1, residues 75-84), TM1i (the intracellular section (i) of TM1, residues 85-97), TM2i (residues 105-117), TM2m (residues 118-126), TM2e (residues 127-131), TM3e (residues 140-148), TM3m (residues 149-157), TM3i (residues 158-172), TM4i (residues 183-193), TM4m (residues 194-200), TM4e (residues 201-207), TM5e (residues 229-240), TM5m (residues 241-248), TM5i (residues 249-259), TM6i (residues 275-293), TM6m (residues 294-301), TM6e (residues 302-307), TM7e (residues 314-323), TM7m (residues 324-331), and TM7i (residues 332-341).

We assembled the representative ensembles of frames for analysis by randomly selecting 5,000 frames with replacement (bootstrapping) for each condition from all the trajectories of that condition, which was repeated 10 times. The same datasets were used for all the geometric

calculations and analyses. The presented results are the average of the 10 bootstrap samplings.

Pairwise Root Mean Square Deviations (RMSDs) can avoid the bias of a single reference. To evaluate the stability of ligand binding, we aligned all possible pairs of the representative MD frames for a given condition according to the C $\alpha$  atoms of the binding site residues of hMOR: Thr122<sup>2.56</sup>, Phe125<sup>2.59</sup>, Gln126<sup>2.60</sup>, Asn129<sup>2.63</sup>, Trp135<sup>EL1.50</sup>, Val145<sup>3.28</sup>, Ile146<sup>3.29</sup>, Asp149<sup>3.32</sup>, Tyr150<sup>3.33</sup>, Met153<sup>3.36</sup>, Asp218<sup>EL2.49</sup>, Cys219<sup>EL2.50</sup>, Trp295<sup>6.48</sup>, Ile298<sup>6.51</sup>, His299<sup>6.52</sup>, Trp320<sup>7.35</sup>, His321<sup>7.36</sup>, Ile324<sup>7.39</sup>, Gly327<sup>7.42</sup>, and Tyr328<sup>7.43</sup>, then calculated the RMSD based on the ligand heavy atoms.

## **2.7. MM/GBSA calculation**

Binding free energies between the bound ligands and the hMOR were estimated with the Molecular mechanics/generalized Born surface area calculations (MM/GBSA) method, using the same force field in the MD simulations for the proteins and ligands, but with VSGB2.1 solvation model [46]. We extracted frames every 3 ns from the production runs to carry out the MM/GBSA calculations using the `thermal_mmgbasa.py` script from the Schrodinger suite. The binding free energies for each condition were the averages of the selected frames.

### 3. Results

#### 3.1. Fentanyl and its analogs favor the *cis-amide* configuration

Previous MD simulation studies showed that the amide bond of fentanyl could be stable in either the *trans* or *cis* configuration (**Fig. 1D**) in the MOR binding pocket, without any reported transition between these two conformations [19-23]. These results suggest the transition between the *trans*- and *cis-amide* configurations may have a relatively high energy barrier to overcome in the MD simulations, but these studies did not evaluate which conformation has lower energy. While the *trans* configuration of the amide bond in proteins (peptide bond) usually has lower energy, interestingly in a crystal structure of a computationally designed fentanyl binding protein, the amide bond of the bound fentanyl molecule is in the *cis-amide* configuration [55].

Metadynamics simulation is an enhanced sampling method that can efficiently overcome energy barriers by adding time-dependent bias potential acting on selected collective variables (CVs) [56]. Thus, to thoroughly understand the energy landscape of the fentanyl conformation, we carried out metadynamics simulations with a fentanyl molecule immersed in a water box (see Methods). In these simulations, we defined two CVs, CV1 is the dihedral angle of the amide bond, while CV2 is the dihedral angle between aniline and piperidine (**Fig. 2C**).

As expected, in our metadynamics simulation results plotted on a 2D free energy surface (FES) (**Fig. 2A**), we observed that CV1 has two energy minima, near 0° (*trans-amide*, referred to as the “T” state below) and 180° (*cis-amide*, the “C” state). Interestingly, CV2 has two minima as well, near -80° (denoted as the “L” state) and 105° (the “H” state). The examination of the FES indicates that the C state has more than 2 kcal/mol lower energy than the T state, while the L state has lower energy and a wider distribution than the H state (**Fig. 2A** and **Table S1**). Thus, on the FES determined by CV1 and CV2, the C state of CV1, in combination with L state of CV2 (referred to as CL), has the globally lowest energy (**Fig. 2A** and **Table S1**).

Using the Dijkstra's algorithm, we identified the minimum free energy paths (MFEP) [57] between the energy minima and calculated the height of the energy barrier along each of such paths on the FES (see Methods). The results show that the transition between the CL and CH states has a significantly lower energy barrier than other transitions, while the C to T transitions (both of the CH to TH and CL to TL MFEPs) have more than 10 kcal/mol energy barrier (**Fig. 2A** and **Table S2**).

### 3.2. 3-methyl and 4-carbomethoxy modifications change the energy landscape

To understand the impact of the modifications of the fentanyl scaffold on the FES, we carried out similar metadynamics simulations of three fentanyl analogs with either or both of 3-methyl and 4-carbomethoxy modifications. Carfentanil has a carbomethoxy group at the 4-position of the piperidine ring (**Fig. S1**). Compared to the FES of fentanyl, carfentanil has a similar CV1 profile, i.e., the T and C states are similarly located, while the C states always have lower energy than the T states (**Fig. 2B, Table S1**). However, carfentanil has a drastically different CV2 profile from that of fentanyl, suggesting significant impacts of the modifications on both the conformation and the flexibility of the scaffold. Specifically, the FES regions corresponding to the H states of fentanyl are high-energy forbidden regions for carfentanil. Further, an energy barrier arises in the middle of the L state and splits the state into two, which we termed L1 and L2 states. The L1 and L2 states are located near  $-10^\circ$  and  $-110^\circ$ , respectively. Given the same CV1 state (either the T or C state), the L1 and L2 states of carfentanil have comparable energies (**Table S1**). On the FES of carfentanil, the identifications of MFEPs and calculations of energy barriers show that the transition from the TL1 to CL1 state, which is favored in the MOR binding site (see below), has more than 2 kcal/mol lower energy barrier than the TL to CL transition of fentanyl (**Table S2**), suggesting the carbomethoxy modification may facilitate this transition. The additional methyl group on the piperidine ring of (3S,4R)-lofentanil further

lowered the energy barrier of the TL1 to CL1 state transition to ~7 kcal/mol, while that for (3R,4S)-lofentanil is similar to carfentanil (**Table S2**).

In addition to the 4-carbomethoxy modification, lofentanil has an extra methyl group at the 3-position of the piperidine ring, the chirality of which can result in the (3S,4R)-, (3R,4S)-, (3S,4S)-, and (3R,4R)-isomers of the compound (**Fig. S1**). Overall, these lofentanil isomers have similar FESs as that of carfentanil, especially the two trans ((3S,4S)- and (3R,4R)-) isomers (**Fig. 3B**). However, given the same CV1 state (either the T or C state), the L1 state of (3S,4R)-lofentanil has ~6 kcal/mol higher energy than its L2 state, while (3R,4S)-lofentanil has a reversed trend. In contrast, the L1 and L2 states of the trans isomers have only minor differences, demonstrating less impact of the 3-methyl modification when it is at the equatorial position of the piperidine ring. For all four isomers, their energetic differences between the most favored C states (e.g., CL2 for (3S,4R)-lofentanil and CL1 for (3R,4S)-lofentanil) and the T states are larger than that of fentanyl (**Table S1**). On their FESs, the identifications of MFEPs and calculations of energy barrier show that the additional methyl group on the piperidine ring of (3S,4R)-lofentanil further lowered the energy barrier of the TL1 to CL1 state transition to ~7 kcal/mol, while that for (3R,4S)-lofentanil is similar to carfentanil (**Table S2**).

To further dissect the roles of 3-methyl and 4-carbomethoxy in altering the FES, we performed metadynamics simulations of ((3S,4R)-, (3R,4S)-, (3S,4S)-, and (3R,4R)-isomers of 3-methylfentanyl. For the two cis ((3S,4R)- and (3R,4S)-) isomers, their FESs are similar to that of fentanyl. However, the positions of their L and H states of CV2 are altered, with those of (3S,4R) moved slightly downwards and those of (3R,4S) moved upwards. In addition, the TL states of 3-methylfentanyl have slightly narrower distributions than that of fentanyl (**Fig. 3A**). Interestingly, the minima of the L states (both TL and CL) on the FES of (3R,4S)-3-methylfentanyl are pushed to similar minima positions of the L1 states of carfentanil and lofentanil, while those of (3S,4R)-3-methylfentanyl are pushed to those of the L2 states (**Fig. 3** and **Table S1**). These different

impacts are consistent with L1 and L2 states having lower energies for (3R,4S)- and (3S,4R)-lofentanil, respectively. For the two trans isomers of 3-methylfentanyl, while some shifts of the L and H states are observed, they are relatively small and correspond to similar profiles of the trans isomers of lofentanil.

Taken together, the C state is the most favored state for fentanyl and all its studied analogs, while the modifications on the piperidine ring in carfentanil and lofentanil make this trend even stronger and lower the energy barrier for the transition from the T to C state. While this manuscript was being prepared, an updated OPLS force field (OPLS4) became available [44]. Using OPLS4, we carried out the same set of metadynamics simulations and analyses and found similar results and conclusions as those described above using OPLS3e (**Figs. S2 and S3, Tables S1 and S2**).

### **3.3. Fentanyl can be stable in two opposite binding orientations in the MOR binding pocket**

To comprehensively evaluate the possible binding poses of fentanyl in the active conformation of the MOR, we first docked fentanyl in the cryo-EM structure of the MOR-Gi complex (PDB 6DDF) [15]. By selecting and then manually adjusting the docked poses, we then established fentanyl poses in both the APF and FPA orientations and in both *trans*- and *cis-amide* configurations, as proposed by previous studies [19-23] (**Fig. 1B-D**). In addition, Vo et al. showed that the protonation state of the His<sup>6.52</sup> might have a significant impact on the fentanyl binding pose [23], which prompted us to consider two neutral protonation states (HIE and HID) of His<sup>6.52</sup> in our study as well. Thus, we built the fentanyl bound MOR-Gi complex models in 8 conditions (**Table S3**). For example, the APF<sub>DT</sub> condition has the bound fentanyl molecule in the APF orientation and the *trans-amide* (subscript “T”) configuration, with His<sup>6.52</sup> of the MOR in the HID state (subscript “D”). For each condition, we immersed the resulting models in the explicit



lipid bilayer simulation environment, and collected multiple prolonged MD simulation trajectories, using either or both OPLS3e and OPLS4 force fields (**Table S3**). For the condition that we have both OPLS3e and OPLS4 data, we did not find any noticeable difference resulting from different force fields. We analyzed the data separately but drew the conclusions by integrating all the results.

To evaluate the stability of binding modes, we calculated the pairwise ligand RMSDs of all possible pairs of MD frames of the representative ensembles for each condition (see Methods). Our results show that fentanyl in the APF *cis-amide* conditions (both APF<sub>EC</sub> and APF<sub>DC</sub>, “E” and “D” in the subscripts represent the His<sup>6.52</sup> in its HIE and HID forms, respectively) are very stable with the pairwise ligand RMSDs of ~1.0 Å (**Figure 4A**). Interestingly, the bound fentanyl in the APF<sub>ET</sub> condition has a tendency to transition to the *cis-amide* configuration (**Fig. S5**), therefore this condition is not considered to be stable for further analysis. We then carried out MM/GBSA binding energy calculations for the same set of representative MD frame ensembles of each condition. The results show that the APF<sub>DC</sub> condition has the most favored binding energy, and the APF<sub>EC</sub> and APF<sub>DT</sub> conditions have 2.5 and 8.1 kcal/mol higher energies ( $\Delta\Delta G$ ), respectively. Thus, both the pairwise ligand RMSD and MM/GBSA results are consistent with the findings from our metadynamics simulations (**Fig. 2A** and **Table S1**) in which we found that the *cis-amide* configuration (C state) has lower energy. When comparing the APF<sub>EC</sub> and APF<sub>DC</sub> conditions, we found the bottom of the binding pocket near His299<sup>6.52</sup> is less dynamic in APF<sub>DC</sub> than in APF<sub>EC</sub>. In particular, the distribution of His299<sup>6.52</sup>  $\chi_1$  rotamer in APF<sub>DC</sub> is tighter than in APF<sub>EC</sub>, which also results in a slightly different orientation of Trp295<sup>6.48</sup>  $\chi_2$  (**Fig. S5**).

In contrast to the APF conditions, among the FPA conditions of fentanyl, only FPA<sub>DT</sub> appears to be a reasonably stable condition with a pairwise ligand RMSD of 1.8 Å, while the other three FPA conditions have drastically higher RMSDs (**Figure 4B**). This trend is reflected on the MM/GBSA calculation results in which the FPA<sub>EC</sub>, FPA<sub>DC</sub>, and FPA<sub>ET</sub> conditions have more than

6 kcal/mol higher energies than FPA<sub>DT</sub>. However, the relative stability of fentanyl in FPA<sub>DT</sub> is surprising given our findings from the metadynamics simulations that show the *trans-amide* configuration (T state) has higher energy (**Fig. 2A**). From our inspection of the FPA<sub>DC</sub> condition, we found that the bound fentanyl molecule in the *trans-amide* configuration forms a hydrogen bond (H-bond) interaction with the sidechain of either Gln126<sup>2.60</sup> or Asn129<sup>2.63</sup> (**Figs. 4D and S5**), which compensates the less favored *trans-amide* configuration. Similar to what we observed between the APF<sub>EC</sub> and APF<sub>DC</sub> conditions, the bottom of the binding pocket in FPA<sub>ET</sub> is more dynamic than in FPA<sub>DT</sub>, with the His299<sup>6.52</sup>  $\chi_1$  in wider distribution (**Fig. S6**).

In summary, we found that fentanyl can be stable in both APF and FPA orientations, with the APF<sub>DC</sub> and FPA<sub>DT</sub> conditions being more favored than the other conditions in each orientation. While the bound fentanyl in both APF<sub>DC</sub> and FPA<sub>DT</sub> conditions form the ionic interaction with Asp149<sup>3.32</sup>, and several other residues in the OBS [58], our detailed contact frequency analysis (see Method) indicate that several residues form distinct interactions either in the APF or FPA poses (**Table 1**).

We then collected previously reported mutagenesis work relevant to fentanyl binding at the MOR by extracting the curated information from GPCRdb [59], as well as carrying out our own literature search (**Table S4**). By comparing the frequently contacting residues in APF and FPA poses, we found mutations of the residues that are not directly involved in interacting with either pose, Ile<sup>4.56</sup>, Val<sup>4.60</sup>, and Lys<sup>6.58</sup> have no effect on fentanyl binding [60, 61]. However, the substitutions of His<sup>6.52</sup> to Asn or Gln have no effect as well, indicating a polar residue can be tolerated at this position, while the aromatic property of His is not critical [62]. Interestingly, Ala mutation of residue His<sup>7.36</sup>, which interacts with the bound fentanyl in the FPA<sub>DT</sub> condition but has no chance of interacting in APF<sub>DC</sub> in our simulations, resulted in significant disruption of the ohmefentanyl binding at the MOR [41] (**Table S4**). From our modeling the ohmefentanyl pose in the MOR binding site, in either the APF or FPA pose, the potential interaction with His<sup>7.36</sup> could

not be from the extra modifications of ohmefentanyl on the fentanyl scaffold, i.e., the 3-methyl of the piperidine ring and 2-hydroxy on the linker between phenyl and piperidine (**Fig. S7**). Thus, the FPA pose may explain the His<sup>7.36</sup>Ala mutagenesis data better, however, we cannot exclude the possibility of indirect effect of the mutation.

### 3.4. The APF *cis-amide* binding poses of carfentanil and lofentanil are more stable

To characterize the impact of modifications on the fentanyl scaffold on the binding pose preferences at the MOR, we then carried out MD simulations of the MOR in complex with carfentanil, (3S,4R)- or (3R,4S)-lofentanil, each in all 8 conditions as those for the MOR-fentanyl complex (**Table S3**).

In the APF *trans-amide* conditions (both APF<sub>ET</sub> and APF<sub>DT</sub>), both carfentanil and (3S,4R)-lofentanil could not stay in the *trans-amide* configuration and transitioned to *cis-amide* in all the trajectories within 3  $\mu$ s, while the transitions in the APF<sub>ET</sub> condition were noticeably faster than in APF<sub>DT</sub> (**Fig. S5**). This is consistent with the results of our metadynamics simulations that show the differences between *cis-amide* and *trans-amide* configurations are higher for carfentanil and lofentanil than for fentanyl (**Table S1**), while the transitions from the T to C state are easier, i.e., having lower energy barriers than those of fentanyl (**Table S2**).

In the FPA *trans-amide* conditions, FPA<sub>ET</sub> is not stable for carfentanil and both isomers of lofentanil, and the bound compounds in the majority of the FPA<sub>ET</sub> trajectories transitioned to the *cis-amide* configuration. In the FPA<sub>DT</sub> condition, however, while (3S,4R)-lofentanil transitioned to *cis-amide* in all trajectories and (3R,4S)-lofentanil has high pairwise ligand RMSDs (**Fig. 5**), carfentanil can be stable in the FPA<sub>DT</sub> condition in all trajectories as fentanyl, to the extent of our simulations (**Fig. S5**). Indeed, we noticed that carfentanil could form a similar H-bond interaction with either Gln126<sup>2.60</sup> or Asn129<sup>2.63</sup>, as fentanyl in FPA<sub>DT</sub>. An analysis of the dihedral angle between aniline and piperidine (i.e., the CV2 in the metadynamics simulations) of the FPA<sub>DT</sub>

conditions of both fentanyl and carfentanil revealed that these bound ligands form the H-bond with either Gln126<sup>2.60</sup> or Asn129<sup>2.63</sup> only in the TL1 state (**Fig. 6**), which can be significantly populated in the metadynamics simulations (**Fig. 2**). In contrast, the TL1 state of (3S,4R)-lofentanil has at least more than 6 kcal/mol higher energy than the other energy minima on the FES, and is an unstable state (**Fig. 3**, and **Table S1**). The potential H-bonds that can be formed to Gln126<sup>2.60</sup> or Asn129<sup>2.63</sup> could not retain (3S,4R)-lofentanil in this state.

Comparing the APF and FPA *cis-amide* conditions, two FPA conditions (FPA<sub>EC</sub> and FPA<sub>DC</sub>) of carfentanil and both lofentanil isomers have significantly higher pairwise ligand RMSDs than two APF conditions, indicating the former are likely not stable poses (**Fig. 5**). Interestingly, in the MM/GBSA calculations, however, we found the APF<sub>EC</sub> condition is slightly more favored than APF<sub>DC</sub> for carfentanil, and lofentanil (APF<sub>EC</sub> has 1.9, 2.6, and 1.7 kcal/mol lower energy than APF<sub>DC</sub> for carfentanil, (3S,4R)-lofentanil, and (3R,4S)-lofentanil, respectively), which is different from the situation in fentanyl.

For these two preferred APF *cis-amide* conditions, the analysis of the MD simulation results of the MOR complexes shows that carfentanil and both isomers of lofentanil stay in their CL1 states and never get into the CL2 state, while the CL state of fentanyl is in a much wider distribution (**Fig. 6**). From the FES derived from the metadynamics simulations of these compounds alone in the absence of the receptor, we note that the CL1 state is the most preferred state for (3R,4S)-lofentanil, while the CL1 state has only slightly higher energy than the CL2 state for carfentanil. However, the CL1 state of (3S,4R)-lofentanil has more than 6 kcal/mol higher than its CL2 state (**Fig. 2** and **Table S1**). Thus, the CL1 state of (3S,4R)-lofentanil bound in the MOR binding pocket is likely stabilized by the interactions with the receptor residues.

Thus, carfentanil is like fentanyl and can be stable in both the APF and FPA orientations, but both isoforms of lofentanil can only be in the APF orientation due the conformational restraints rendered by the extra methyl group on the piperidine ring.

Carfentanil has been reported to have at least 6-fold [3, 32] or even ~50-fold [31] higher binding affinity than fentanyl at the MOR, while lofentanil was found to have an even slightly higher affinity than carfentanil [32]. By comparing the contact frequencies in the APF<sub>DC</sub> conditions of carfentanil and lofentanil versus that of fentanyl, we found the carbomethoxy group of carfentanil and the cis-isomers of lofentanil forms a strong interaction with Trp320<sup>7,35</sup> (**Fig. 5** and **Table 1**), which is likely the structural basis for their enhanced affinities at the MOR. The extra methyl group of (3R,4S)-lofentanil forms a weak interaction with Tyr150<sup>3,33</sup>, which may further stabilize the APF<sub>DC</sub> condition compared to those of carfentanil, though only marginally (see Discussion).

### 3.5. MOR conformational change when binding to the fentanyl and its analogs

DAMGO, which is bound in the cryo-EM structure of the MOR-Gi complex used as the main template for this study, has been found to be an unbiased full agonist [63], while fentanyl has been proposed to be an  $\beta$ -arrestin-biased agonist at the MOR [7]. In order to fully understand the functional consequence of fentanyl binding, it is critical to evaluate whether fentanyl binding would result in a different receptor conformation compared to that stabilized by DAMGO. Thus, we compared the conformations of the MOR-fentanyl and MOR-DAMGO models. For the former, we chose the more favored MOR-fentanyl APF<sub>DC</sub> condition; for the latter, based on the original cryo-EM structure, we immersed a refined MOR-DAMGO model in a lipid bilayer and carried out extensive MD simulations using the same simulation protocols as those for the MOR-fentanyl models (**Table S3**). In these control simulations of the MOR-DAMGO model, we found only limited changes from the original conformation revealed by the cryo-EM structure, as

demonstrated by the low and quickly plateaued RMSD evolutions along the MOR-DAMGO MD trajectories (**Fig. S8**).

We adapted a previously developed in-house tool, the Protein Interaction Analyzer (see Methods), to compare the representative MD frame ensembles of the MOR-fentanyl and MOR-DAMGO models, with a focus on the regions in or near the binding pocket (see Methods). We found the conformations of the OBS in two models are very similar (the region enclosed by the dotted box in **Fig. 7D**); however, there are significant changes in a secondary binding pocket (SBP) near the extracellular portion of TM1 (TM1e, see the definition in Method section), TM2e, TM3e, and TM7e. Our inspections of the models indicated that these changes likely resulted from an outward rearrangement of Trp135<sup>EL1.50</sup> due to its interaction with the phenyl moiety of fentanyl, while Tyr130<sup>2.64</sup> rotates inward, compared to their configurations in the presence of the bound DAMGO (**Fig. 7**). These coordinated changes are reflected in the shortened distance between Tyr130<sup>2.64</sup> and Trp135<sup>EL1.50</sup> in the presence of fentanyl (**Fig. 7C**). We further quantified the differential effects of fentanyl and DAMGO bindings by plotting the distances of TM1e-TM3e versus TM2e-TM7e in two conditions. We found fentanyl reduced the TM1e-TM3e distance, elongated the TM2e-TM7e distance, and therefore changed both the size and shape of the SBP (**Fig. 7E,F**).

## 4. Discussion

The mechanistic understanding of the binding of fentanyl and its analogs at the MOR is the foundation to reveal how the impact of these abused synthetic opioids is propagated toward the intracellular side of the receptor to initiate downstream signaling cascades, which will then elicit both beneficial analgesic and a variety of undesired side effects. However, in the absence of high-resolution structural information of the MOR bound with fentanyl, previous molecular modeling and simulation studies have proposed drastically different fentanyl binding modes, both in orientations within the binding pocket and ligand conformations [19-23]. To this end, we carried out a systematic computational study to investigate the preferred conformations of fentanyl and how these conformations are being accommodated in the MOR binding pocket, by characterizing the free energy landscape of fentanyl conformations with metadynamics simulations, as well as performing long-timescale MD simulations to compare 8 possible binding conditions. Our results indicate that the APF<sub>DC</sub> binding condition is preferred, while the FPA<sub>DT</sub> condition is also possible, with the slightly unfavored *trans-amide* configuration of fentanyl stabilized by forming a H-bond with Gln126<sup>2.60</sup> or Asn129<sup>2.63</sup>.

Our APF *cis-amide* poses of fentanyl are largely consistent with the fentanyl pose reported by Ricarte et al., which was based on the modeling and the simulations with the structure 5C1M [22], and we found that the same set of hMOR residues interact with fentanyl (**Table 1**). Our FPA<sub>DT</sub> is in a similar orientation as the pose proposed by Vo et al., whom, however, found that when His<sup>6.52</sup> was in the HID form, fentanyl could move deeper and form a hydrogen bond between the protonated piperidine amine to the N $\epsilon$  atom of His<sup>6.52</sup>, instead of forming a salt bridge with Asp<sup>3.32</sup> [23]. While in our simulations, the bound fentanyl in the FPA<sub>DT</sub> condition retains the interaction with Asp<sup>3.32</sup> persistently. Our results show that the protonation state of His<sup>6.52</sup>, had only limited impact on the APF pose of fentanyl and carfentanil (**Figs. 4 and 5**); however, the HID form facilitated stabilizing the FPA pose (**Fig. 4**).

The drastic improved affinity of 3-methylfentanyl over fentanyl, which is not observed in lofentanil over carfentanil, indicate that modifications at the 3- and 4-positions may have overlapping roles in improving the potency; at least they do not have additive effects. If (3R,4S)-lofentanil has higher affinity than (3S,4R)-lofentanil (see Introduction), our results may provide the structural basis for why lofentanil prefers the (3R,4S)- but not (3S,4R)- configuration in binding to the MOR. Carfentanil and both (3S,4R)- and (3R,4S)-isomers of lofentanil all stay in the CL1 state in the APF poses when bound in the MOR binding pocket (**Fig. 6**). However, the CL1 state of (3R,4S)-lofentanil on the FES has lower energy than the CL2 state, while its (3S,4R)-isomer has the reversed trend (**Fig. 3B**). Thus, if the (3S,4R)-lofentanil has to be in the CL1 state in the MOR binding pocket, it is not in its preferred state and may result in lower binding affinity. In addition, the stronger interaction with Tyr<sup>3.33</sup>, when the ligand is in the (3R,4S)-configuration (**Table 1**), is expected to slightly improve the affinity.

In this study, we compared the results from metadynamics and MD simulations of fentanyl in the absence and presence of the receptor, respectively, and combined them to establish the structure-activity relationship (SAR) of the fentanyl scaffold at the MOR. The FES deduced from metadynamics simulations lay the foundation for our understanding of how fentanyl and its analogs would behave in the binding pocket of the MOR. The most favored poses of fentanyl and its analogs are consistent with the global minima on the FES, the FES guided us to seek the specific ligand-receptor interactions that may compensate the unfavored ligand conformations. Such an approach to thoroughly characterize the energy landscape of the ligand conformation has not been well appreciated. While long-timescale MD simulations is powerful in revealing ligand-induced receptor conformation changes to accommodate specific ligand scaffolds, it is not trivial to identify the proper binding pose with MD simulations in the first place, such as our previous work in identifying the binding modes of paroxetine at the serotonin transporter [64]. Indeed, even at relatively long timescales, we have not observed any transition



between APF and FPA orientations. Thus, this combined approach provides a framework not only for the current fentanyl study but can also be applied to other SAR studies at other GPCRs. In a companion manuscript, by combining the experimental and computational approaches, we found that the alkyl modifications of the amide moiety of the fentanyl scaffold affect the efficacy at the MOR (Xie et al., manuscript in preparation). Together, our findings start to establish a SAR of fentanyl binding at the MOR, which will facilitate our prediction and understanding of the potential toxicity of emerging novel synthetic opioids based on the fentanyl scaffold. Such insights will also contribute to developing new, safer analgesics with desired pharmacological properties.

**Author Contribution**

B.X. and L.S. designed the study. B.X. and A.G. carried out computational modeling, simulations, and analysis. All authors took part in interpreting the results. B.X. and L.S. wrote the manuscript.

**Declarations of Competing Interests**


No potential conflict of interest was reported by the authors.

**Acknowledgements**


We thank Michael Baumann, Istvan Ujvary, Kenner Rice, and Arthur Jacobson for insightful discussions. Support for this research was provided by the National Institute on Drug Abuse—Intramural Research Program, Z1A DA000606 (L.S.). This work utilized the computational resources of the NIH HPC Biowulf cluster (<http://hpc.nih.gov>).

## Figures and Figure Legends


**Figure 1. Two possible binding orientations of fentanyl in the orthosteric binding site of  $\mu$ -opioid receptor.** (A) An overview of a fentanyl bound MOR-Gi complex. The binding pocket is highlighted with a dashed box. (B) and (C) are schematic orientations of how a bound fentanyl can be oriented in the MOR binding pocket. F, P, and A stand for phenyl, piperidine, and amide moieties of fentanyl, respectively. Two binding orientations, APF (B) and FPA (C), have been proposed in previous studies (see text). In addition, the rotation of the amide bond results in *cis*-amide and *trans*-amide configurations of fentanyl, as shown in panel D.




**Figure 2. Metadynamics simulations of fentanyl and carfentanil reveal their possible conformations.** The free energy surfaces (FESs) reconstructed from the metadynamics results are shown in panels A-B for the indicated ligands. For each FES, we identified four minima, labelled as TL, TH, CL, and CH for fentanyl, TL1, TL2, CL1, and CL2 for the other analogs. The dihedral angle of the amide bond is defined as CV1, and that between aniline and piperidine as CV2, as shown in panel C. The stable states of fentanyl and carfentanil in the MOR binding pocket are CL and CL1, respectively (**Fig. 6**). The minimum free energy paths (MFEP) between the TL and CL states for fentanyl and the TL1 and CL1 states for the other analogs are plotted with dotted curves on each FES. The conformations corresponding to the energy minima are shown in panel C for fentanyl, and panel D for carfentanil.




**Figure 3. Metadynamics simulations of 3-methylfentanyl and lofentanil demonstrate the impact of 3-methyl modification.** The FESs reconstructed from the metadynamics results are shown in panels A-B for the ligands in the indicated configurations. For each FES, we identified four minima, labelled as TL, TH, CL, and CH for 3-methylfentanyl, TL1, TL2, CL1, and CL2 for lofentanil. The stable state of the *cis*-isomers of lofentanil in the MOR binding pocket is CL1 (Fig. 6). The MFEP between the TL1 and CL1 states for the *cis*-isomers of lofentanil are plotted with dotted curves on each FES. The conformations corresponding to the energy minima are shown in panels C and D for representative 3-methylfentanyl and lofentanil isomers, respectively.



**Figure 4. APF<sub>DC</sub> and FPA<sub>DT</sub> are the more stable poses in each orientation.** The average pairwise ligand RMSDs for each indicated condition are shown for the APF and FPA orientations in panels A and B, respectively. The darker colored bars are OPLS3e results, and those of the lighter colored bars are OPLS4 results. The APF<sub>DC</sub> and FPA<sub>DT</sub> are the more stable conditions for APF and FPA orientations, respectively, and the fentanyl binding poses in these two conditions are demonstrated in panels C and D.




**Figure 5. Carfentanil and lofentanil prefer the APF orientation.** The average pairwise ligand RMSDs for each indicated ligand and condition are in panels A-C. APF<sub>DC</sub> conditions for each analog are shown in panels D-F. As a reference, the fentanyl binding pose (green) is superimposed in each panel. The carbomethoxy moiety of these analogs form an additional contact to Trp320<sup>7.35</sup> (large circles in panels D-F), which is likely responsible for the higher potencies of these analogs compared to fentanyl. In addition, (3R,4S)-lofentanil has an interaction between its 3-methyl to Tyr150<sup>3.33</sup> (small circle in panel F).






**Figure 6. The distributions of the CV1 and CV2 dihedral angles of fentanyl and its analogs bound in the MOR.** Only the relatively stable conditions in the MD simulations, APF<sub>EC</sub>, APF<sub>DC</sub>, FPA<sub>ET</sub>, and FPA<sub>DT</sub>, are shown for each indicated ligands. Darker dots are the OPLS3e results and lighter ones are the OPLS4 results. See Figs. 2 and 3 for the CV1 and CV2 definitions.





**Figure 7. Fentanyl induced divergent conformation near the binding pocket.** (A) An overview the superimposed DAMGO and fentanyl binding poses in the MOR. (B) A zoom-in view demonstrating the diverged positions and orientations of Tyr130<sup>2.64</sup> and Trp135<sup>EL1.50</sup> when the receptor is bound with either DAMGO or fentanyl (APF<sub>DC</sub>). Panel C shows the center-of-mass distances between the phenyl ring of the indole moiety of Trp135<sup>EL1.50</sup> and the sidechain of Tyr130<sup>2.64</sup> in the fentanyl and DAMGO bound conditions. In the analysis with the Protein Interaction Analyzer, we calculated the center-of-mass distances among the extracellular and middle subsegments of the MOR. The differences of these distances between the DAMGO and fentanyl bound conditions (i.e., distance<sub>DAMGO</sub> - distance<sub>fentanyl</sub>) are plotted on a heatmap shown in panel D. Specifically, the differences in the orthosteric binding site enclosed by TMs 3, 5, 6, and 7 (dotted box) are small, however, significant differences are detected in a secondary binding pocket encircled by TMs 1, 2, 3, and 7. In particular, the TM1e-TM3e distance is larger in the presence of the bound DAMGO, while TM2e-TM7e is larger in the fentanyl-bound condition. These two distances are indicated by the dotted lines in panel A, and their distributions are shown in panels E and F for DAMGO- and fentanyl-bound conditions, respectively.



## Tables

**Table 1. The contact frequencies of the residues interacting with fentanyl and its analogs in the hMOR.** In a molecular dynamics (MD) simulation frame, if the shortest heavy-atom distance between the ligand and any given residue of the MOR was within 5 Å, we defined that the ligand forms an interaction with this residue. The residues that have at least one contact frequency > 0.6 in any indicated condition are included in this table. The results shown here are based on the simulations with the OPLS4 force field. For the APF poses, we combined the results of APF<sub>EC</sub> and APF<sub>DC</sub> into APF<sub>C</sub> for each indicated ligand. The differences between the analogs and fentanyl in their APF<sub>C</sub> conditions are shown in the “- fentanyl” columns.

Residue	fentanyl		carfentanil		(3S,4R)-lofentanil		(3R,4S)-lofentanil	
	APF <sub>C</sub>	FPA <sub>DT</sub>	APF <sub>C</sub>	- fentanyl	APF <sub>C</sub>	- fentanyl	APF <sub>C</sub>	- fentanyl
Thr122 <sup>2.56</sup>	0.32	0.98	0.13	-0.19	0.02	-0.30	0.16	-0.16
Phe125 <sup>2.59</sup>	0.08	0.97	0.14	0.06	0.12	0.05	0.10	0.02
Gln126 <sup>2.60</sup>	1.00	0.99	1.00	0.00	1.00	0.00	1.00	0.00
Asn129 <sup>2.63</sup>	0.96	0.89	0.98	0.02	0.94	-0.02	0.99	0.03
Tyr130 <sup>2.64</sup>	0.47	0.14	0.54	0.08	0.74	0.28	0.56	0.09
Trp135 <sup>EL1.50</sup>	0.99	1.00	0.98	-0.02	0.90	-0.09	0.96	-0.04
Val145 <sup>3.28</sup>	0.97	0.99	0.98	0.01	0.92	-0.05	0.94	-0.03
Ile146 <sup>3.29</sup>	0.99	1.00	0.99	0.01	0.99	0.01	0.98	-0.01
Asp149 <sup>3.32</sup>	1.00	1.00	1.00	0.00	1.00	0.00	1.00	0.00
Tyr150 <sup>3.33</sup>	0.28	0.97	0.49	0.21	0.60	0.32	0.87	0.59
Asn152 <sup>3.35</sup>	0.74	0.00	0.48	-0.26	0.26	-0.48	0.55	-0.19
Met153 <sup>3.36</sup>	1.00	0.99	1.00	0.00	1.00	0.00	1.00	0.00
Cys219 <sup>EL2.50</sup>	1.00	1.00	1.00	-0.01	0.98	-0.03	0.98	-0.03
Val238 <sup>5.42</sup>	1.00	0.12	0.96	-0.04	0.88	-0.12	0.92	-0.08
Trp295 <sup>6.48</sup>	0.95	0.59	0.91	-0.04	0.96	0.01	0.95	0.00
Ile298 <sup>6.51</sup>	1.00	0.98	1.00	0.00	1.00	0.00	1.00	0.00
His299 <sup>6.52</sup>	1.00	0.68	1.00	0.00	1.00	0.01	1.00	0.01
Val302 <sup>6.55</sup>	0.98	0.11	0.83	-0.15	0.94	-0.04	0.89	-0.09
Trp320 <sup>7.35</sup>	0.43	0.73	1.00	0.57	1.00	0.57	1.00	0.57
His321 <sup>7.36</sup>	0.00	0.86	0.00	0.00	0.00	0.00	0.00	0.00
Ile324 <sup>7.39</sup>	1.00	1.00	1.00	0.00	1.00	-0.01	1.00	0.00
Gly327 <sup>7.42</sup>	0.99	0.84	0.99	0.00	0.98	-0.01	1.00	0.02
Tyr328 <sup>7.43</sup>	1.00	1.00	1.00	0.00	1.00	0.00	1.00	0.00

## References

1. Pasternak, G.W. and Y.X. Pan, *Mu opioids and their receptors: evolution of a concept*. Pharmacol Rev, 2013. **65**(4): p. 1257-317.
2. Stanley, T.H., *The fentanyl story*. J Pain, 2014. **15**(12): p. 1215-26.
3. Baumann, M.H., T.A. Kopajtic, and B.K. Madras, *Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis*. Trends Pharmacol Sci, 2018. **39**(12): p. 995-998.
4. The Drug Enforcement Administration's (DEA) Special Testing and Research Laboratory's Emerging Trends Program. *DEA Emerging Threat Reports*. 2020, May 1; Available from: <https://ndews.umd.edu/resources/dea-emerging-threat-reports>.
5. Comer, S.D. and C.M. Cahill, *Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment*. Neurosci Biobehav Rev, 2019. **106**: p. 49-57.
6. Haley, D.F. and R. Saitz, *The Opioid Epidemic During the COVID-19 Pandemic*. JAMA, 2020. **324**(16): p. 1615-1617.
7. Schmid, C.L., et al., *Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics*. Cell, 2017. **171**(5): p. 1165-1175 e13.
8. Ehrlich, A.T., et al., *Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons*. iScience, 2019. **14**: p. 47-57.
9. Gillis, A., et al., *Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists*. Sci Signal, 2020. **13**(625).
10. Stahl, E.L. and L.M. Bohn, *Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists*. Biochemistry, 2021.
11. Subramanian, G., et al., *Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor*. J Med Chem, 2000. **43**(3): p. 381-91.

12. Dosen-Micovic, L., M. Ivanovic, and V. Micovic, *Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor*. Bioorg Med Chem, 2006. **14**(9): p. 2887-95.
13. Huang, W., et al., *Structural insights into micro-opioid receptor activation*. Nature, 2015. **524**(7565): p. 315-21.
14. Manglik, A., et al., *Crystal structure of the micro-opioid receptor bound to a morphinan antagonist*. Nature, 2012.
15. Koehl, A., et al., *Structure of the micro-opioid receptor-Gi protein complex*. Nature, 2018. **558**(7711): p. 547-552.
16. Kapoor, A., D. Provasi, and M. Filizola, *Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of  $\mu$ -Opioid Receptor*. Mol Pharmacol, 2020. **98**(4): p. 475-486.
17. Mafi, A., S.K. Kim, and W.A. Goddard, 3rd, *Mechanism of  $\beta$ -arrestin recruitment by the  $\mu$ -opioid G protein-coupled receptor*. Proc Natl Acad Sci U S A, 2020. **117**(28): p. 16346-16355.
18. Ellis, C.R., et al., *Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking*. PLoS One, 2018. **13**(5): p. e0197734.
19. Lipinski, P.F.J., et al., *Molecular dynamics of fentanyl bound to mu-opioid receptor*. J Mol Model, 2019. **25**(5): p. 144.
20. de Waal, P.W., et al., *Molecular mechanisms of fentanyl mediated beta-arrestin biased signaling*. PLoS Comput Biol, 2020. **16**(4): p. e1007394.
21. Podlewska, S., et al., *Molecular Modeling of  $\mu$  Opioid Receptor Ligands with Various Functional Properties: PZM21, SR-17018, Morphine, and Fentanyl-Simulated Interaction Patterns Confronted with Experimental Data*. Molecules, 2020. **25**(20).

22. Ricarte, A., J.A.R. Dalton, and J. Giraldo, *Structural Assessment of Agonist Efficacy in the  $\mu$ -Opioid Receptor: Morphine and Fentanyl Elicit Different Activation Patterns*. J Chem Inf Model, 2021. **61**(3): p. 1251-1274.
23. Vo, Q.N., et al., *How mu-opioid receptor recognizes fentanyl*. Nat Commun, 2021. **12**(1): p. 984.
24. Eshleman, A.J., et al., *Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors*. Biochem Pharmacol, 2020. **182**: p. 114293.
25. Ballesteros, J.A. and H. Weinstein. *Modeling Transmembrane Helix Contacts in GPCR*. in *Biophysical Society Meeting*. 1995. San Francisco, CA.
26. Van Bever, W.F., C.J. Niemegeers, and P.A. Janssen, *Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide*. J Med Chem, 1974. **17**(10): p. 1047-51.
27. Zawilska, J.B., et al., *Carfentanil - from an animal anesthetic to a deadly illicit drug*. Forensic Sci Int, 2021. **320**: p. 110715.
28. Wax, P.M., C.E. Becker, and S.C. Curry, *Unexpected "gas" casualties in Moscow: a medical toxicology perspective*. Ann Emerg Med, 2003. **41**(5): p. 700-5.
29. Jin, W.Q., et al., *Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives*. Sci Sin, 1981. **24**(5): p. 710-20.
30. Xu, H., et al., *(+)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: evidence for pseudoallosteric modulation*. Neuropharmacology, 1991. **30**(5): p. 455-62.
31. Maguire, P., et al., *Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors*. Eur J Pharmacol, 1992. **213**(2): p. 219-25.

32. Yeadon, M. and I. Kitchen, *Differences in the characteristics of opioid receptor binding in the rat and marmoset*. J Pharm Pharmacol, 1988. **40**(10): p. 736-9.
33. Lalinde, N., et al., *Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics*. J Med Chem, 1990. **33**(10): p. 2876-82.
34. Janssen, P.A., *Potent, new analgesics, tailor-made for different purposes*. Acta Anaesthesiol Scand, 1982. **26**(3): p. 262-8.
35. Leysen, J.E., W. Gommeren, and C.J. Niemegeers, *[3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord*. Eur J Pharmacol, 1983. **87**(2-3): p. 209-25.
36. Tollenaere, J.P., H. Moereels, and M. Van Loon, *On conformation analysis, molecular graphics, fentanyl and its derivatives*. Prog Drug Res, 1986. **30**: p. 91-126.
37. Leysen, J.E. and P.M. Laduron, *Receptor binding properties in vitro and in vivo of some long-acting opiates*. Arch Int Pharmacodyn Ther, 1978. **232**(2): p. 243-6.
38. Stahl, K.D., et al., *Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs*. Eur J Pharmacol, 1977. **46**(3): p. 199-205.
39. Leysen, J., P. Laduron, and C. Niemegeers, *Receptor binding properties in vitro and in vivo of new long acting narcotic analgesics*, in *Characteristics and Function of Opioids*. 1978, Elsevier North-Holland Biomedical Press Amsterdam. p. 479-482.
40. Flippenanderson, J.L., et al., *X-Ray Crystal-Structures of Potent Opioid Receptor Ligands - Etonitazene, Cis-(+)-3-Methylfentanyl, Etorphine, Diprenorphine, and Buprenorphine*. Heterocycles, 1994. **39**(2): p. 751-766.
41. Xu, H., et al., *Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands*. Synapse, 1999. **32**(1): p. 23-8.

42. Bowers, K.J., et al. *Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters*. in *ACM/IEEE SC 2006 Conference (SC'06)*. 2006.
43. Roos, K., et al., *OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules*. *J Chem Theory Comput*, 2019. **15**(3): p. 1863-1874.
44. Lu, C., et al., *OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space*. *J Chem Theory Comput*, 2021.
45. Dijkstra, E.W., *A note on two problems in connexion with graphs*. *Numerische Mathematik*, 1959. **1**(1): p. 269-271.
46. Li, J., et al., *The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling*. *Proteins*, 2011. **79**(10): p. 2794-812.
47. John, B. and A. Sali, *Comparative protein structure modeling by iterative alignment, model building and model assessment*. *Nucleic Acids Res*, 2003. **31**(14): p. 3982-92.
48. Olsson, M.H., et al., *PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions*. *J Chem Theory Comput*, 2011. **7**(2): p. 525-37.
49. Sherman, W., et al., *Novel procedure for modeling ligand/receptor induced fit effects*. *J Med Chem*, 2006. **49**(2): p. 534-53.
50. Dror, R.O., et al., *Activation mechanism of the beta2-adrenergic receptor*. *Proc Natl Acad Sci U S A*, 2011. **108**(46): p. 18684-9.
51. Lane, J.R., et al., *Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism*. *Elife*, 2020. **9**.
52. Humphrey, W., A. Dalke, and K. Schulten, *VMD: visual molecular dynamics*. *J Mol Graph*, 1996. **14**(1): p. 33-8, 27-8.
53. Stolzenberg, S., et al., *Computational approaches to detect allosteric pathways in transmembrane molecular machines*. *Biochim Biophys Acta*, 2016. **1858**(7 Pt B): p. 1652-62.



54. Michino, M., et al., *Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor*. J Med Chem, 2017. **60**(2): p. 580-593.
55. Bick, M.J., et al., *Computational design of environmental sensors for the potent opioid fentanyl*. Elife, 2017. **6**.
56. Laio, A. and M. Parrinello, *Escaping free-energy minima*. Proc Natl Acad Sci U S A, 2002. **99**(20): p. 12562-6.
57. Branduardi, D. and J.D. Faraldo-Gómez, *String method for calculation of minimum free-energy paths in Cartesian space in freely-tumbling systems*. Journal of chemical theory and computation, 2013. **9**(9): p. 4140-4154.
58. Michino, M., et al., *What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?* Pharmacol Rev, 2015. **67**(1): p. 198-213.
59. Pándy-Szekeres, G., et al., *GPCRdb in 2018: adding GPCR structure models and ligands*. Nucleic Acids Research, 2017. **46**(D1): p. D440-D446.
60. Mansour, A., et al., *Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study*. J Neurochem, 1997. **68**(1): p. 344-53.
61. Bonner, G., F. Meng, and H. Akil, *Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop*. Eur J Pharmacol, 2000. **403**(1-2): p. 37-44.
62. Spivak, C.E., et al., *Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity*. Mol Pharmacol, 1997. **52**(6): p. 983-92.
63. Kelly, E., *Efficacy and ligand bias at the mu-opioid receptor*. Br J Pharmacol, 2013. **169**(7): p. 1430-46.
64. Abramyan, A.M., et al., *Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics*. Neuropharmacology, 2019. **161**: p. 107411.